Research Papers:

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

Xiaolu Meng, Zhuo Mao, Xin Li, Dandan Zhong, Min Li, Yingli Jia, Jing Wei, Baoxue Yang and Hong Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:40305-40317. https://doi.org/10.18632/oncotarget.16928

Metrics: PDF 2290 views  |   HTML 2827 views  |   ?  


Xiaolu Meng1, Zhuo Mao2, Xin Li3, Dandan Zhong1, Min Li1, Yingli Jia1, Jing Wei2, Baoxue Yang1 and Hong Zhou1

1Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, P.R. China

2Tianjin Key Laboratory for Modern Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, P.R. China

3Drug Clinical Trial Institution, The Affiliated Hospital of Qingdao University, Qingdao, 266003, P.R. China

Correspondence to:

Hong Zhou, email: [email protected]

Keywords: baicalein, hyperuricemia, uric acid, nephropathy, xanthine oxidoreductase

Received: January 06, 2017     Accepted: March 24, 2017     Published: April 07, 2017


Baicalein, a natural flavonoid, is structurally advantageous for binding to xanthine oxidoreductase. In our study, molecular docking analysis and Surface Plasmon Resonance revealed a direct interaction between baicalein and xanthine oxidoreductase. Moreover, 50 mg/kg/d baicalein treatment significantly suppressed the viability of xanthine oxidoreductase in hyperuricemia mouse model. The data showed that baicalein remarkably prevented renal dysfunction, ameliorated kidney fibrosis, alleviated epithelial-mesenchymal transition and oxidative stress in hyperuricemia mice. Thus, we concluded that baicalein executed a kidney-protection action in hyperuricemia and therefore may be used as a therapeutic alternative for hyperuricemic nephropathy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16928